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Outcomes After Aortic Valve Replacement 
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Regurgitation
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Young-Nam Youn , MD, PhD; Seung Hyun Lee , MD, PhD
BACKGROUND: The objectives of the present study were (1) to evaluate the echocardiographic prognostic factors associated 
with improved left ventricular (LV) systolic function after aortic valve replacement, and (2) to compare the long-term outcomes 
after aortic valve replacement in chronic aortic regurgitation (AR) patients with or without LV dysfunction.
METHODS AND RESULTS: A total of 280 patients who underwent aortic valve replacement because of chronic aortic regurgitation 
were studied. Patients with reduced LV systolic function (LV ejection fraction [LVEF] <50%; group reduced LVEF [rEF]; N=80) 
were compared with those with preserved LV systolic function (LVEF ≥50%; group preserved LVEF; N=200). Postoperative 
clinical outcomes, overall survival, and freedom from cardiac death were compared. Postoperative echocardiographic ex-
aminations were reviewed, and changes in echocardiographic parameters were analyzed. The parameters related to LVEF 
improvement or normalization were evaluated, and risk factors affecting long-term survival were identified. Follow-up was 
complete in 100% of patients, with a median follow-up of 104.8 months. Overall and cardiac mortality-free survival rates at 
postoperative 10 years were 80.1% and 92.9% and 87.3% and 97.2% in groups rEF and preserved LVEF, respectively (P=0.036 
and P=0.058, respectively). LVEF tended to decrease in the early postoperative period but improved thereafter in both groups. 
Preoperative early diastolic transmitral flow velocity/mitral annular tissue velocity ratio was a parameter of postoperative im-
provement or normalization of LVEF in all patients (area under the curve, 0.719; P=0.003) and in group rEF patients (area under 
the curve, 0.726; P=0.011) with a cutoff value of 12.73. Preoperative early diastolic transmitral flow velocity/mitral annular tis-
sue velocity ratio also was the parameter of overall survival in all patients (hazard ratio [HR], 1.08; P=0.001) and in group rEF 
patients (HR, 1.08; P=0.005).
CONCLUSIONS: Long-term outcomes and survival after aortic valve replacement were related to preoperative LV function in 
patients with chronic aortic regurgitation. Preoperative early diastolic transmitral flow velocity/mitral annular tissue velocity 
ratio was correlated with the postoperative improvement or normalization of LVEF and long-term survival, especially in group 
rEF patients.
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Aortic valve replacement (AVR) is recommended in patients with symptomatic chronic aortic regurgitation (AR) and in asymptomatic pa-
tients with AR with left ventricular (LV) dysfunction 
or dilatation.1 Although previous studies have shown 
that AVR in these patients is related to better survival 
than expected from the natural progression of the 
disease,2,3 preoperative LV dysfunction and enlarged 
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LV dimensions were known to be negative prog-
nostic indicators for patients undergoing surgery.4,5 
Recent studies showed that the prognosis after AVR 
in patients with severe AR with preoperative LV dys-
function was similar to that in patients without LV 
dysfunction, and that LV function increased postop-
eratively in patients with LV dysfunction.6,7 However, 
LV dysfunction in patients with chronic AR is likely 
to span a spectrum of disease severity because LV 
dysfunction gradually worsens, and identifying the 
timing of irreversible LV dysfunction is an import-
ant consideration. Current guidelines for treatment 
of chronic AR might be insufficient for detecting if 
the irreversible LV dysfunction has taken place. Little 
is known of when the irreversible dysfunction takes 
place and about the optimal timing of AVR in patients 
with chronic AR because the development of LV 
dysfunction frequently precedes the onset of symp-
toms.8 The parameters of preoperative AR quantifi-
cation or LV function have not yet been thoroughly 
investigated, and their relevance to the postoperative 
prognosis has been little studied.9,10
The aims of the present study were (1) to evaluate 
the echocardiographic prognostic factors associated 
with improved LV systolic function after AVR and (2) to 
compare the long-term outcomes after AVR in patients 
with chronic AR with or without LV dysfunction.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
The study protocol was reviewed by the Institutional 
Review Board and approved as a minimal-risk retro-
spective study (approval No. 4-2019-0337) that did not 
require individual consent on the basis of the institu-
tional guidelines for waiving consent.
Among 919 patients who underwent AVR with-
out another valve surgery from January 2001 to 
December 2014, 280 who underwent AVR because 
of chronic AR were included in this study. Patients 
who underwent concomitant coronary artery bypass 
grafting (N=21) or ascending aortic surgery (N=51) 
were included. Patients who had acute AR caused by 
aortic dissection or aortic valve perforation caused 
by endocarditis (N=92), greater than moderate aor-
tic valve stenosis (N=399), combined mitral valvular 
disease (N=104), a history of previous valve surgery 
(N=11), and missed echocardiographic data (N=33) 
were excluded. The patients were divided into the 
reduced LV ejection fraction (LVEF) group (group 
rEF; LVEF <50%) and preserved LVEF group (group 
pEF; LVEF ≥50%), according to preoperative LVEF 
(Figure 1).
Patients underwent regular postoperative fol-
low-up examinations through the outpatient clinic 
at 3- to 4-month intervals, and their survival status 
or reporting of cardiovascular events was collected 
by reviewing electronic medical records. In addition, 
data for the vital statistics and death from cardiovas-
cular diseases were obtained from death certificates 
CLINICAL PERSPECTIVE
What Is New?
• This study is the first study evaluating the rel-
evance of preoperative tissue Doppler early 
diastolic transmitral flow velocity/mitral annular 
tissue velocity ratio to the postoperative im-
provement of left ventricular function and long-
term outcomes after aortic valve replacement in 
patients with chronic aortic regurgitation.
• Preoperative early diastolic transmitral flow ve-
locity/mitral annular tissue velocity ratio was 
correlated with the postoperative improvement 
or normalization of left ventricular ejection frac-
tion and long-term survival.
• Long-term outcomes after aortic valve replace-
ment were related to preoperative left ven-
tricular function in patients with chronic aortic 
regurgitation.
What Are the Clinical Implications?
• Early surgical treatment before the progres-
sion of left ventricular diastolic dysfunction may 
improve long-term outcomes in patients with 
chronic aortic regurgitation.
• Preoperative early diastolic transmitral flow ve-
locity/mitral annular tissue velocity ratio value 
might provide valuable information in deter-
mining the optimal timing of surgical treatment 
for chronic aortic regurgitation, especially in 
patients with reduced left ventricular ejection 
fraction.
Nonstandard Abbreviations and Acronyms
AR aortic regurgitation
AVR aortic valve replacement
E/e’ early diastolic transmitral flow velocity/
mitral annular tissue velocity ratio
LVEDD left ventricular end-diastolic diameter
LVESD left ventricular end-systolic diameter
LVFS left ventricular fractional shortening
pEF preserved left ventricular ejection 
fraction
rEF reduced left ventricular ejection fraction
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available at Statistics Korea, a central organization for 
statistics under the Ministry of Strategy and Finance. 
The clinical and echocardiographic follow-up exam-
inations were closed on July 31, 2019. The follow-up 
data were complete in 100% (280/280) of patients, 
with a median follow-up duration of 104.8 (interquar-
tile range, 72.7–152.2) months. Postoperative clinical 
outcomes, overall survival, freedom from cardiac 
death, and cardiac events were compared between 
the groups. Operative death was defined as death 
occurring within 30  days after AVR or during the 
same hospital stay. Cardiac death was defined as 
any death related to cardiac events, including sud-
den death during the follow-up. Cardiac event was 
defined as readmission because of heart failure, re-
operation because of prosthetic valve failure, a need 
for cardiac intervention, such as percutaneous coro-
nary intervention or coronary artery bypass grafting, 
pacemaker implantation, or cardiac death.
Early (median, 6.0 [interquartile range, 4.0–7.0] 
days), 1-year (median, 11.1 [interquartile range, 
7.0–13.2] months), 3-year (median, 35.9 [interquar-
tile range, 30.4–41.3] months), and 5-year (median, 
65.6 [interquartile range, 58.5–76.8] months) post-
operative echocardiographic examinations were per-
formed in 96.4% (270/280), 78.6% (220/280), 65.0% 
(182/280), and 67.5% (189/280) of patients, respec-
tively. The echocardiographic parameters included 
LVEF calculated by modified Simpson method, LV 
end-diastolic diameter (LVEDD), LV end-systolic di-
ameter (LVESD), LV fractional shortening (LVFS; 
[LVEDD−LVESD/LVEDD]×100), and the early diastolic 
transmitral flow velocity/mitral annular tissue veloc-
ity (E/e′) ratio. We used septal E/e′ rather than lat-
eral E/e′ to indicate patient’s LV diastolic function. 
Preoperative E/e′ was not available in 16 patients. 
The parameter of LVEF improvement or normaliza-
tion was evaluated, and risk factors affecting long-
term survival were identified.
Statistical Analysis
Statistical analysis was performed with R software, 
version 3.6.0. Continuous data were expressed as 
the mean±SD for normally distributed variables or 
as medians (interquartile ranges) for nonnormally 
distributed variables, according to the Shapiro-Wilk 
test; and categoric data were expressed as counts 
(percentages). Comparisons between continuous 
variables were made using Student t test for nor-
mally distributed data or the Wilcoxon rank-sum 
test for nonnormally distributed data, on the basis 
of the Shapiro-Wilk test. Categoric variables were 
compared using a χ2 test. When ≥20% of expected 
counts were ≤5, however, the Fisher exact test was 
used.
The differences between preoperative and post-
operative echocardiographic parameters were calcu-
lated, and the differences over time between groups 
were analyzed using repeated measures of ANOVA. 
Each model included the group, time, and interac-
tion term between group and time variables (stats 
package).
Increased LVEF >10 percentage points compared 
with preoperative LVEF or LVEF ≥50% at 3 years or 
later after postoperative echocardiography was re-
garded as “improved or normalized LVEF” based on 
previous studies analyzing serial changes in LV vol-
umes or LVEF in patients with heart failure,11,12 and 
used as an outcome variable in receiver operating 
characteristic curve analysis. The receiver oper-
ating characteristic curve analysis of preoperative 
parameters for postoperative LVEF improvement 
or normalization was performed, and cutoff val-
ues of preoperative parameters and area under the 
curve (AUC) were identified (Epi package and pROC 
package).
Overall survival, freedom from cardiac death, and 
freedom from cardiac event were analyzed using 
Kaplan-Meier survival curves, and comparisons be-
tween the groups were performed using the log-rank 
test. Univariable and multivariable Cox proportional 
hazard models were used to identify risk factors that 
affected long-term survival. Appropriate variables in 
Figure 1. Summary flow diagram of patients.
AS indicates aortic stenosis; AVR, aortic valve replacement; EF, 
ejection fraction; pEF, preserved left ventricular EF (EF ≥50%); 
and rEF, reduced left ventricular EF (EF <50%).
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A total of 280 patients were divided into group rEF 
(N=80) and group pEF (N=200), according to pre-
operative LVEF. There were no differences in preop-
erative patient characteristics between the 2 groups, 
except for a lower New York Heart Association func-
tional class in group rEF than in group pEF (P=0.001) 
(Table 1).
Operative Data and Early Clinical 
Outcomes
There were 5 operative mortalities, and intergroup 
differences were not found between the groups 
rEF and pEF (P=0.943). The median cardiopul-
monary bypass time and aortic cross-clamp time 
were 98.5 (interquartile range, 84.0–117.3) minutes 
and 70.0 (interquartile range, 60.0–86.0) minutes, 
respectively (P=0.926 and P=0.245, respectively). 
Mechanical prosthetic valves were more fre-
quently implanted in group pEF than in group rEF 
(P=0.008). Combined operations were performed in 
78 patients (coronary artery bypass grafting, N=21; 
surgery on ascending aorta, N=51; ventricular sep-
tal defect closure, N=2; atrial septal defect closure, 
N=1; coronary arteriovenous fistula closure, N=1; 
sinus of Valsalva aneurysm repair, N=1; and Cox-
Maze III procedure, N=1), and showed no intergroup 
difference (P=0.598). The intensive care unit stay 
was significantly longer in group rEF than in group 
pEF (P=0.033) (Table 2).
Postoperative Changes in 
Echocardiographic Parameters
The LVEF was directly correlated with LVFS 
(P<0.001), and inversely correlated with LVEDD 
(P<0.001), LVESD (P<0.001), and E/e′ (P=0.005) pre-
operatively (Figure  S1). The LVEF and LVFS tended 
to decrease in the early postoperative period and in-
creased at ≥1 year during the follow-up period, and 
LVEDD and LVESD tended to decrease after AVR. In 
contrast, E/e′ showed no significant differences dur-
ing the postoperative periods. When the changes of 
echocardiographic parameters over time between 
groups were compared, group rEF patients showed 
higher changes in improved LVEF and LVFS and de-
creased LVEDD and LVESD than group pEF patients 
(P<0.001). However, the changes of E/e′ over time 
were not significantly different between the 2 groups 
(P=0.416) (Table 3).
Echocardiographic Parameters 
Associated With Postoperative LVEF 
Improvement or Normalization
Improved or normalized LVEF was observed in 92.7% 
(215/232) of all patients. Optimum cutoff values of pre-
operative LVEDD, LVESD, LVFS, and E/e′ for improve-
ment or normalization of LVEF were 74 mm (sensitivity, 
59.1%; specificity, 76.5%), 52  mm (sensitivity, 50.7%; 
specificity, 94.1%), 25% (sensitivity, 71.2%; specific-
ity, 82.4%), and 12.73 (sensitivity, 68.3%; specificity, 
76.5%), respectively. Preoperative LVEDD, LVESD, 
LVFS, and E/e′ were significantly associated with 
postoperative improvement or normalization of LVEF, 
Table 1. Comparison of the Patients’ Preoperative 






Age, y 60.9 (52.9–68.6) 59.0 (47.0–66.8) 0.100
Women 23 (28.8) 66 (33.0) 0.584
BMI, kg/m2 23.3 (20.8–25.1) 23.6 (21.8–25.8) 0.170
BSA, m2 1.7±0.2 1.7±0.2 0.294
Smoking 0.953
Nonsmoker 50 (62.5) 124 (62.0)
Ex-smoker 12 (15.0) 28 (14.0)
Current smoker 18 (22.5) 48 (24.0)
Atrial fibrillation 8 (10.0) 10 (5.0) 0.204
Hypertension 41 (51.2) 103 (51.5) >0.999
Diabetes mellitus 7 (8.8) 23 (11.5) 0.647
Chronic renal failure 6 (7.5) 10 (5.0) 0.597
Preoperative 
creatinine, mg/dL
1.0 (0.9–1.2) 0.9 (0.8–1.1) 0.146
History of stroke 5 (6.2) 12 (6.0) >0.999
Coronary artery 
disease
14 (17.5) 29 (14.5) 0.656
Peripheral vascular 
obstructive disease
2 (2.5) 5 (2.5) >0.999
Chronic obstructive 
lung disease
7 (8.8) 13 (6.5) 0.687
NYHA class 0.001
1 0 (0.0) 6 (3.0)
2 15 (18.8) 78 (39.0)
3 56 (70.0) 106 (53.0)
4 9 (11.2) 10 (5.0)
Preoperative AR grade 0.382
2 4 (5.0) 18 (9.0)
3 38 (47.5) 101 (50.5)
4 38 (47.5) 81 (40.5)
Bicuspid aortic valve 19 (23.8) 41 (20.5) 0.662
Data are given as median (interquartile range) or number (percentage). 
AR indicates aortic regurgitation; BMI, body mass index; BSA, body surface 
area; NYHA, New York Heart Association; pEF, preserved left ventricular 
ejection fraction (left ventricular ejection fraction ≥50%); and rEF, reduced left 
ventricular ejection fraction (left ventricular ejection fraction <50%).
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with AUC of 0.733 (P<0.001), 0.794 (P<0.001), 0.794 
(P<0.001), and 0.719 (P=0.003), respectively (Figure 2). 
In group rEF, improved or normalized LVEF was ob-
served in 78.5% (51/65) of patients at 3 years or later 
postoperatively. Of preoperative echocardiographic 
parameters for group rEF, E/e′ was associated with 
improved or normalized LVEF postoperatively (AUC, 
0.726; P=0.011), and the optimum cutoff value was 
12.73 (sensitivity, 70.2%; specificity, 78.6%). Other pa-
rameters, such as LVEDD, LVESD, and LVFS, failed to 
show relation with improved or normalized LVEF post-
operatively (Figure 3).
Overall Survival, Freedom From Cardiac 
Death, and Freedom From Cardiac Events
All-cause mortality occurred in 44 patients (group rEF 
versus pEF, 18/80 versus 26/200), including 9 cardiac 
deaths (group rEF versus pEF, 5/80 versus 4/200), dur-
ing the follow-up period. Overall postoperative survival 
rates at 5 and 10 years were 86.2% and 80.1% in group 
rEF, respectively, and 94.0% and 87.3% in group pEF, 
respectively (P=0.036), although statistical significance 
became marginal after age adjustment (P=0.058) 
(Figure 4). Cardiac mortality-free postoperative survival 
rates at 5 and 10 years were 94.5% and 92.9% in group 
rEF, respectively, and 98.4% and 97.2% in group pEF, 
respectively. A significant intergroup difference in car-
diac mortality-free survival rates was found between the 
groups after age adjustment (P=0.028). Freedom from 
postoperative cardiac event rates at 5 and 10 years was 
88.7% and 78.9% in group rEF, respectively, and 95.0% 
and 87.2% in group pEF, respectively. No significant 
difference in freedom from cardiac events was found 
between the groups after age adjustment (P=0.099) 
(Figure  4). Multivariable analysis by Cox proportional 
hazard model revealed that age (P<0.001), creatinine 
level (P=0.007), combined coronary artery disease 
(P<0.001), and New York Heart Association class 
(P=0.001) were significant parameters of all-cause mor-
tality in all study patients (Table 4). Multivariable analysis 
in group rEF showed E/e′ to be a significant parameter 
of all-cause mortality (P=0.005) (Table 5).
Echocardiographic Parameters Associated 
With Postoperative LVEF Improvement or 
Normalization in Late-Referral Group
Subgroup analysis was performed with “late-referral 
group” that included patients with New York Heart 
Association class ≥3 (N=89) or LVESD >50 mm (N=181) 
other than group rEF patients.
In patients with New York Heart Association class 
≥3, optimum cutoff values of preoperative LVEDD, 
LVESD, LVEF, and E/e′ for improvement or normal-
ization of LVEF were 68 mm (sensitivity, 64.7%; spec-
ificity, 75.0%), 46 mm (sensitivity, 47.8%; specificity, 
91.7%), 49% (sensitivity, 70.6%; specificity, 83.3%), 
and 12.73 (sensitivity, 63.3%; specificity, 83.3%), re-
spectively. Preoperative LVEDD, LVESD, LVEF, and 
E/e′ were significantly associated with postoperative 
improvement or normalization of LVEF in these pa-
tients with AUC of 0.731 (P=0.008), 0.726 (P=0.009), 
0.720 (P=0.012), and 0.718 (P=0.013), respectively 
(Figure S1). In patients with LVESD >50 mm, optimum 
cutoff values of preoperative LVEDD, LVESD, LVEF, 
and E/e′ for improvement or normalization of LVEF 
were 82  mm (sensitivity, 85.2%; specificity, 27.3%), 
55  mm (sensitivity, 34.4%; specificity, 90.9%), 47% 
(sensitivity, 47.5%; specificity, 90.9%), and 9.67 (sen-
sitivity, 41.1%; specificity, 100.0%), respectively. Only 
preoperative E/e’ was associated with postopera-
tive improvement or normalization of LVEF in these 
patients, with a marginal significance (AUC, 0.669; 
P=0.080). Other parameters were not associated 
with postoperative improvement or normalization of 
LVEF (Figure S2).
DISCUSSION
This study demonstrated 4 main findings. First, the 
LVEF decreased in the early postoperative period 
and increased at ≥1  year during the follow-up pe-
riod. Second, the reduced LVEF group showed lower 
overall postoperative survival and cardiac mortality-
free survival rates than the preserved LVEF group at 
Table 2. Comparison of the Patients’ Operative Data and Early Clinical Outcomes Between the rEF and pEF Groups
Variable Group rEF (N=80) Group pEF (N=200) P Value
Cardiopulmonary bypass time, min 99.0 (87.5–112.5) 98.0 (82.0–119.0) 0.926
Arterial cross-clamp time, min 69.0 (59.5–79.5) 71.0 (60.0–91.5) 0.245
Mechanical prosthesis 46 (57.5) 149 (74.5) 0.008
Co-operations 20 (25.0) 58 (29.0) 0.598
Length of ICU stay, d 2.0 (2.0–3.0) 2.0 (1.0–2.0) 0.033
Length of hospital stay, d 11.0 (8.0–15.5) 9.0 (8.0–14.0) 0.162
Operative mortality 2 (2.5) 3 (1.5) 0.943
Data are given as median (interquartile range) or number (percentage). ICU indicates intensive care unit; pEF, preserved left ventricular ejection fraction (left 
ventricular ejection fraction ≥50%); and rEF, reduced left ventricular ejection fraction (left ventricular ejection fraction <50%).
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5 and 10 years. Third, preoperative E/e′ was associ-
ated with postoperative improvement or normaliza-
tion of LVEF and all-cause mortality in the reduced 
LVEF group.
Current treatment guidelines for patients with 
chronic AR recommend that AVR is indicated for 
patients with severe AR patients with symptoms or 
LV systolic dysfunction (LVEF <50%), is reasonable 
to be performed in asymptomatic patients with AR 
with normal LV systolic function (LVEF ≥50%) but 
with LVESD >50 mm or indexed LVESD >25 mm/m2, 
and may be considered in asymptomatic patients 
with AR with normal LV systolic function but LVEDD 
>65 mm.1 However, current guidelines might be too 
conservative and hence mistime surgery because 
AVR is a safer procedure than in the past and there 
are evolving surgical options, such as rapid deploy-
ment AVR with newly designed bioprosthetic valve 
to reduce implantation time. Therefore, the optimal 
timing for AVR in patients with chronic AR needs to 
be reevaluated and reassessed.13,14 One recent study 
by Mentias et al, which included 1417 patients with 
greater than grade 3 chronic AR and preserved LVEF, 
showed that the mortality in nonsurgical patients with 
chronic AR significantly and continuously increased 
when indexed LVESD was >20 mm/m2 and proposed 
Figure 2. Receiver operating characteristic (ROC) curves in all patients.
ROC curves were calculated to determine a cutoff value of preoperative left ventricular end-diastolic diameter (LVEDD) (A), preoperative 
left ventricular end-systolic diameter (LVESD) (B), preoperative left ventricular fractional shortening (LVFS) (C), and preoperative early 
diastolic transmitral flow velocity/mitral annular tissue velocity ratio (E/e′) (D) for improvement or normalization of left ventricular 
function. AUC indicates area under the curve.
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a possibility for reassessment of current recommen-
dations for AVR in these patients.15 Another study by 
Yang et al, which included 748 patients with greater 
than moderate chronic AR, showed that the indexed 
LVESD was associated with all-cause mortality and 
the ideal cutoff of the value was less than previously 
recommended.16 Wang et al, in their study of 192 pa-
tients with severe AR, normal LVEF, and severe LV 
dilatation, revealed satisfactory outcomes in these 
patients, but found that LVEF <55% was related to 
poorer prognosis.17
One previous study by Borer et al demonstrated 
that 3  years was necessary for the recovery of LV 
performance in terms of LVEF after AVR for AR.18 The 
present study included 280 patients who underwent 
AVR because of chronic AR and showed similar re-
sults that LVEF tended to decrease in the early post-
operative period and increased thereafter after AVR. 
In the current study, patients with chronic AR with 
grade 2 or higher, most of whom underwent AVR 
during concomitant coronary artery bypass grafting 
or ascending aortic surgery, were included to reflect 
Figure 3. Receiver operating characteristic (ROC) curves in patients with left ventricular (LV) systolic dysfunction 
(preoperative LV ejection fraction <50%).
ROC curves were calculated to determine a cutoff value of preoperative left ventricular end-diastolic diameter (LVEDD) (A), preoperative 
left ventricular end-systolic diameter (LVESD) (B), preoperative left ventricular fractional shortening (LVFS) (C), and preoperative early 
diastolic transmitral flow velocity/mitral annular tissue velocity ratio (E/e′) (D) for improvement or normalization of LV function. AUC 
indicates area under the curve.
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surgeons’ interest in real world. Group rEF patients 
needed a longer intensive care unit stay and showed 
worse overall survival and cardiac mortality-free sur-
vival when compared with group pEF patients. This 
study supports that earlier surgery before the pa-
tient’s LVEF decreases <50% might have a positive 
prognostic impact on the patient’s long-term clinical 
outcomes.
Previous studies have identified preoperative pa-
rameters associated with the prognosis after AVR in 
patients with chronic AR and suggested that preop-
erative diastolic function may have an importance in 
predicting outcomes.19–23 The present study demon-
strated that the optimum cutoff values of LVEDD, 
LVESD, LVFS, and E/e′ for improvement or normaliza-
tion of LV systolic function were 74 mm, 52 mm, 25%, 
Figure 4. Comparison of overall survival (A), cardiac mortality-free survival (B), and freedom from cardiac events (C) 
between preserved left ventricular ejection fraction (LVEF ≥50%) (pEF) and reduced LVEF (LVEF <50%) (rEF) groups, before 
and after age adjustment. 
Table 4. Univariable and Multivariable Parameters of All-Cause Mortality in All Patients
Variables
Univariable Analysis Multivariable Analysis
HR (95% CI) P Value HR (95% CI) P Value
Female sex 1.03 (0.55–1.94) 0.927
Age 1.05 (1.02–1.07) 0.001 1.05 (1.02–1.08) <0.001
BMI 0.96 (0.89–1.04) 0.306
Smoking 1.24 (0.90–1.72) 0.192
Hypertension 1.28 (0.70–2.32) 0.422
Diabetes mellitus 1.95 (0.91–4.21) 0.088
Chronic renal failure 2.71 (1.06–6.89) 0.037
Preoperative creatinine level 1.20 (1.05–1.38) 0.009 1.20 (1.05–1.37) 0.007
History of stroke 2.94 (1.15–7.48) 0.024
Coronary artery disease 3.11 (1.66–5.81) <0.001 3.99 (2.10–7.58) <0.001
Peripheral vascular obstructive disease 2.36 (0.57–9.78) 0.235
Chronic obstructive lung disease 1.26 (0.39–4.08) 0.706
NYHA class 2.43 (1.48–3.99) <0.001 2.51 (1.47–4.29) 0.001
LVEF 0.98 (0.96–1.00) 0.117
LVEDD 0.99 (0.96–1.03) 0.677
LVESD 1.01 (0.98–1.04) 0.642
LVFS 0.97 (0.93–1.02) 0.212
E/e′ 1.08 (1.03–1.13) 0.001
BMI indicates body mass index; E/e′, early mitral inflow velocity/mitral annular early diastolic velocity ratio; HR, hazard ratio; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVFS, left ventricular fractional shortening; and NYHA, 
New York Heart Association.
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and 12.73, respectively, in all patients. Of the preop-
erative variables, the cutoff values of LVEDD, LVESD, 
and LVFS were similar to the current guidelines, and 
performing AVR before the parameters reach these 
cutoff values may be warranted. Measurement of tis-
sue Doppler E/e′, a ratio between early transmitral flow 
velocity and early diastolic mitral annular tissue veloc-
ity, is known to be the most reproducible noninvasive 
method for estimation of LV filling pressure, and is one 
of the key variables recommended for assessment 
of LV diastolic function.24–26 Lateral E/e′ >12 or septal 
E/e′ >15 is known to be associated with a higher likeli-
hood of increased LV filling pressure.26 In the previous 
study, Egbe et al demonstrated that preoperative E/e’ 
>14 was the risk factor of cardiac death after AVR.22 
Similarly, the present study revealed E/e’ to be related 
to all-cause mortality as well as cardiac mortality after 
AVR, and its relevance increased in patients with re-
duced LV systolic function.
The cutoff value of septal E/e′ associated with the 
improvement of normalization of LVEF, 12.73, was 
lower than the known threshold value of LV diastolic 
dysfunction, and this might imply that the earlier con-
sideration of surgical treatment is warranted because 
diastolic dysfunction is known to be associated with 
unfavorable outcomes in various cardiac pathological 
conditions.24,27 In group rEF patients, only E/e′ was 
associated with the improvement or normalization of LV 
systolic function, and other parameters failed to show 
relationship with LV systolic function improvement or 
normalization. The cutoff value of E/e′ associated with 
LV systolic function improvement or normalization in 
group rEF was 12.73, which was identical to the value 
in all patients. In addition, E/e′ was a multivariable pa-
rameter of all-cause mortality in group rEF.
To the best of our knowledge, this study is the 
first to evaluate the relevance of preoperative tissue 
Doppler E/e′ on post-AVR outcomes and LV func-
tion in patients with chronic AR. E/e′ appears to be 
a robust and useful measure that is associated with 
postoperative normalization of LV systolic function and 
overall survival in all patients and in patients with LV 
systolic dysfunction. Furthermore, E/e’ was analyzed 
to be a useful parameter in patients with chronic AR 
with symptoms or LVESD >50 mm as well. E/e’ was 
more strongly associated with postoperative improve-
ment of LV systolic function than other parameters, 
and the cutoff value of E/e’ associated with improve-
ment or normalization of LVEF was lower in patients 
with LVESD >50 mm than other patients (9.67 versus 
12.73). Further study is warranted to clear out this 
result.
This study has limitations that must be recognized. 
First, it was a retrospective study performed at a single 
Table 5. Univariable and Multivariable Parameters of All-Cause Mortality in Patients With LV Systolic Dysfunction 
(Preoperative LVEF <50%)
Variable
Univariable Analysis Multivariable Analysis
HR (95% CI) P Value HR (95% CI) P Value
Female sex 1.53 (0.55–4.25) 0.416
Age 1.01 (0.97–1.06) 0.477
BMI 0.93 (0.80–1.07) 0.288
Smoking 1.33 (0.80–2.20) 0.269
Hypertension 1.96 (0.75–5.13) 0.169
Diabetes mellitus 1.02 (0.23–4.46) 0.977
Chronic renal failure 1.59 (0.36–6.99) 0.536
Preoperative creatinine level 1.43 (0.96–2.14) 0.079
History of stroke 0.82 (0.11–6.21) 0.847
Coronary artery disease 2.57 (0.96–6.91) 0.060
Peripheral vascular obstructive disease 4.54 (0.60–34.66) 0.144
Chronic obstructive lung disease 3.16 (0.89–11.25) 0.075
NYHA class 2.64 (1.12–6.24) 0.027
LVEF 0.96 (0.91–1.01) 0.118
LVEDD 1.04 (0.98–1.10) 0.169
LVESD 1.05 (0.99–1.11) 0.099
LVFS 0.93 (0.84–1.03) 0.161
E/e′ 1.08 (1.02–1.15) 0.005 1.08 (1.02–1.15) 0.005
BMI indicates body mass index; E/e′, early mitral inflow velocity/mitral annular early diastolic velocity ratio; HR, hazard ratio; LV, left ventricular; LVEDD, LV 
end-diastolic diameter; LVEF, LV ejection fraction; LVESD, LV end-systolic diameter; LVFS, LV fractional shortening; and NYHA, New York Heart Association.
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institution. Second, relatively small sample size, short 
echocardiographic follow-up, and absence of strain 
measurement, such as global longitudinal strain, might 
be limitations to generalize this study finding in the daily 
practice. Third, the determined optimal cutoff values of 
parameters were not validated or tested in an indepen-
dent population. Fourth, long-term outcomes, includ-
ing overall survival, could be affected by confounding 
factors because of the group heterogeneity, although 
we performed age-adjusted log-rank tests for the over-
all survival to overcome this limitation. Fifth, using E/e’ 
alone might have a pitfall in the measurement of LV 
diastolic function, especially in circumstances such as 
combined mitral regurgitation, although E/e’ is one of 
the important variables used for assessment of LV di-
astolic dysfunction.25 We excluded patients with prior 
valve surgery or combined mitral valve disease to make 
the study population more homogeneous. However, 
further studies on the impact of other parameters re-
lated to LV diastolic dysfunction on the post-AVR out-
comes may be warranted.
CONCLUSIONS
In patients with chronic AR, long-term clinical outcomes 
and survival after AVR were related to preoperative LV 
function. Preoperative E/e′ was strongly correlated 
with the postoperative improvement or normalization 
of LVEF and long-term survival, especially in patients 
with LVEF <50%. We suggest that these data support 
earlier surgical treatment before the progression of LV 
diastolic dysfunction.
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